레베르 선천성 흑암시 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the leber congenital amaurosis market size was valued at USD 1.31 billion in 2025 and is estimated to grow from USD 1.36 billion in 2026 to reach USD 1.67 billion by 2031, at a CAGR of 4.25% during the forecast period (2026-2031).

This report is Segmented by Treatment Type (Gene Therapy, Pharmacological Therapy, and More), Target Gene (RPE65, CEP290, GUCY2D, and More), End User (Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Market Forecasts are Provided in Terms of Value (USD).

Global Leber Congenital Amaurosis Market Trends and Insights

Rapid Commercial Uptake of Luxturna and Forthcoming Gene-Therapy Approvals

Voretigene neparvovec established proof-of-concept for AAV-mediated ocular gene augmentation and remains a clinical precedent that validates one-time treatment strategies in pediatric-onset blindness. Adoption is shaped by the high list price and the concentration of administration within a network of designated subretinal injection centers. The pipeline is diversifying across multiple LCA genotypes as next-generation constructs pursue pivotal paths backed by regulatory designations. Opus Genetics advanced OPGx-LCA5 with Regenerative Medicine Advanced Therapy status, setting up a pivotal design that aims to convert earlier functional gains into confirmatory outcomes. MeiraGTx reported clinically meaningful visual acuity gains with AAV-AIPL1 in children with LCA4, and the program is being positioned for regulatory review in the United Kingdom and dialogue with U.S. authorities .

Expansion of Newborn, Carrier, and Population Genetic-Testing Panels

Genomic newborn screening programs and expanded carrier testing are broadening the diagnostic funnel for inherited retinal diseases that present in infancy or early childhood. A U.S. pilot, Early Check, showed a measurable yield of actionable findings through genome sequencing in a general newborn cohort, supporting earlier identification of ultra-rare conditions that can inform trial enrollment and clinical surveillance. Carrier screening guidance encourages universal, ethnicity-agnostic approaches for conditions with relevant carrier frequencies, which cover many LCA-associated genes. ACOG affirmed broad support for expanded carrier screening, which aligns obstetric practice with genetic approaches that can identify at-risk families before symptom onset in offspring. Earlier diagnosis and counseling increase the likelihood of timely referral to specialized centers and faster entry into gene-therapy pathways, adding momentum to the Leber congenital amaurosis market.

400k-Plus Per-Eye Therapy Costs Restricting Payer Uptake

The high list price for the only approved ocular gene therapy creates a demanding evidence bar and protracted prior authorization workflows for pediatric patients. Large payers require genetic confirmation and documentation of viable retinal cells before authorizing treatment, and many plans limit retreatment for previously injected eyes. Sponsors have implemented co-pay assistance and referral pathways to charitable support for eligible patients, which helps but does not eliminate administrative friction. Outcomes-based contracts tied to functional vision endpoints have been advanced to reduce payer risk, which shifts focus toward real-world durability. A federal model that centralizes outcomes-based contracting for cell and gene therapies aims to reduce state-level negotiation burden in public coverage programs, creating a precedent that could extend to inherited retinal diseases.

Other drivers and restraints analyzed in the detailed report include:

1. Orphan-Drug, Priority Review, and Rare Pediatric Disease Incentives
2. Rising Venture, Pharma, and Public Funding for Inherited Retinal Disease R&D
3. Scarcity Of Accredited Sub-Retinal Surgery Centers Outside the U.S. and the EU

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Gene therapy captured 41.50% of the Leber congenital amaurosis market share in 2025 and is on track to grow at 4.78% annually through 2031, maintaining leadership in a category shaped by single-dose treatments and rigorous functional endpoints. The premium price point weighs on near-term uptake, but concentrated surgical networks, payer pathways, and clear eligibility criteria create a framework that supports steady adoption in qualified candidates. Evidence continues to accumulate as next-generation constructs demonstrate improvements in pediatric cohorts, including notable gains in visual function for children with AIPL1-associated disease. OPGx-LCA5 progressed under RMAT, and pivotal planning reflects growing confidence in clinically meaningful endpoints for inherited retinal diseases. Pharmacologic options remain limited to supportive care and do not materially change disease trajectory, which reinforces gene therapy's central role in the Leber congenital amaurosis market.

The Leber congenital amaurosis market size for gene therapy is set to expand at a 4.78% CAGR through 2031 as pivotal programs mature and payer pathways evolve. Programs that deploy CRISPR-Cas9 and other editing modalities showed proof-of-concept in defined CEP290 mutations, and sponsors are advancing trial designs that link structural biomarkers with functional gains in vision. Supportive devices and prosthetics have a minor revenue role as sponsors and clinicians focus on preserving or restoring endogenous photoreceptor function in amenable genotypes. Regulatory flexibility around pediatric endpoints and iterative guidance under RMAT support well-designed trials that can read out on meaningful outcomes, which benefits the Leber congenital amaurosis market.

Geography Analysis

North America retained 45.18% in 2025 on the strength of designated treatment networks, high genetic testing penetration, and mature clinical infrastructure for pediatric gene therapy. The limited set of U.S. centers streamlines administration and consolidates experience in dosing and follow-up, which contributes to safety and data consistency. Prior authorization requirements commonly request genetic confirmation and evidence of viable retinal cells, which adds time and administrative steps before dosing. A federal model for outcomes-based contracting seeks to reduce the burden on state programs, which could provide a template for broader access over time. Sponsors engaged in regulatory dialogue for pivotal progression during 2025, signaling continued momentum toward larger confirmatory studies in the Leber congenital amaurosis market.

Europe is the second pillar with established centers that deliver both commercial and investigational therapies for inherited retinal diseases. U.K. pediatric eye hospitals have treated children with AAV-based constructs and continue to collaborate across clinical and academic partners to advance programs toward review. A peer-reviewed report documented significant visual function gains in LCA4 children who received an AAV-mediated AIPL1 construct, highlighting the potential for meaningful pediatric benefit. A large German cohort showed that the diagnostic yield reached 54.3% in the most recent decade, which underscores the synergy between broader panels and improved phenotyping. European reference networks and professional societies coordinate shared care pathways and virtual clinics that support consistent standards across member countries in the Leber congenital amaurosis market.

Asia-Pacific is expected to grow at 4.67% through 2031 with government-backed manufacturing capacity and expanding newborn screening programs that raise early identification. The Leber congenital amaurosis market size in Asia-Pacific is forecast to expand at a 4.67% CAGR as facilities in Australia provide GMP-grade vector production that supports clinical and commercial supply for regional and international sponsors. Australia funded national newborn screening enhancements that broaden the scope of early detection and lay the groundwork for timely referral in inherited disorders. As designated treatment infrastructure outside Western hubs continues to scale, APAC's influence on clinical development and supply logistics is poised to rise within the Leber congenital amaurosis market.

1. 4D Molecular Therapeutics, Inc.
2. Abbvie
3. Adverum Biotechnologies, Inc.
4. Aerie Pharmaceuticals, Inc.
5. Astellas Pharma
6. Atsena Therapeutics, Inc.
7. Beacon Therapeutics plc
8. Biogen
9. Editas Medicine, Inc.
10. Editas Medicine Allergan Collaboration
11. GenSight Biologics S.A.
12. Horama S.A.
13. MeiraGTx Holdings plc
14. Novartis
15. Ocugen, Inc.
16. Pfizer
17. ProQR Therapeutics N.V.
18. REGENXBIO
19. Santen Pharmaceuticals
20. Spark Therapeutics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapid commercial uptake of Luxturna and forthcoming gene-therapy approvals
  • 4.2.2 Expansion of newborn, carrier and population genetic-testing panels
  • 4.2.3 Orphan-drug, Priority Review and Rare Pediatric Disease incentives
  • 4.2.4 Rising venture, pharma and public funding for inherited retinal disease R&D
  • 4.2.5 Asia-Pacific viral-vector manufacturing hubs delivering 20-30 % lower COGS
  • 4.2.6 AI-guided adaptive-optics retinal imaging platforms
• 4.3 Market Restraints
  • 4.3.1 $400k-Plus Per-Eye Therapy Costs Restricting Payer Uptake
  • 4.3.2 Scarcity Of Accredited Sub-Retinal Surgery Centers Outside U.S./EU
  • 4.3.3 Global Viral-Vector Fill-Finish Capacity Bottlenecks Delaying Launches
  • 4.3.4 Highly Fragmented Mutation Landscape Diluting ROI For Long-Tail Gene Targets
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts

• 5.1 By Treatment Type
  • 5.1.1 Gene Therapy
  • 5.1.2 Pharmacological Therapy
  • 5.1.3 Retinal Prosthesis
  • 5.1.4 Assistive Devices
  • 5.1.5 Other Supportive Treatments
• 5.2 By Target Gene
  • 5.2.1 RPE65
  • 5.2.2 CEP290
  • 5.2.3 GUCY2D
  • 5.2.4 AIPL1
  • 5.2.5 CRB1
  • 5.2.6 RPGRIP1
  • 5.2.7 Others
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Specialized Eye Clinics
  • 5.3.3 Ophthalmology Research Centers
  • 5.3.4 Home Care Settings
  • 5.3.5 Others
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 4D Molecular Therapeutics, Inc.
  • 6.3.2 AbbVie Inc.
  • 6.3.3 Adverum Biotechnologies, Inc.
  • 6.3.4 Aerie Pharmaceuticals, Inc.
  • 6.3.5 Astellas Pharma Inc.
  • 6.3.6 Atsena Therapeutics, Inc.
  • 6.3.7 Beacon Therapeutics plc
  • 6.3.8 Biogen Inc.
  • 6.3.9 Editas Medicine, Inc.
  • 6.3.10 Editas Medicine Allergan Collaboration
  • 6.3.11 GenSight Biologics S.A.
  • 6.3.12 Horama S.A.
  • 6.3.13 MeiraGTx Holdings plc
  • 6.3.14 Novartis AG
  • 6.3.15 Ocugen, Inc.
  • 6.3.16 Pfizer Inc.
  • 6.3.17 ProQR Therapeutics N.V.
  • 6.3.18 REGENXBIO Inc.
  • 6.3.19 Santen Pharmaceutical Co., Ltd.
  • 6.3.20 Spark Therapeutics, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment